Before any medicine reaches a pharmacy shelf, it passes through a long chain of checks that most patients never see – tests for purity, stability, effectiveness and safety, carried out by pharmaceutical companies and reviewed by national and international regulators. Neither doctors nor patients make this call alone; it is a structured, accountable process that protects public health at every stage of a drug's life cycle.

This regulatory work is not separate from health management – it is one of its core functions. A health system that delivers quality care and uses its resources well depends on pharmaceutical companies and regulators doing their part to keep medicines effective and safe. Understanding how that system works is essential for anyone involved in healthcare, pharmacy or public health policy.

The Arab British Fellowship Training Academy offers this course as part of a wider set of programs in health management and health and safety, designed for professionals who want a clear, practical grasp of how drug regulation actually functions.

By the end of this course, participants will be able to:

• Explain why formal drug regulation matters for patient safety and for health management as a whole.
• Identify the main global regulatory bodies – the FDA, the European Medicines Evaluation Agency (EMEA), and the Japanese Pharmaceutical Affairs Office – and how they interact with local regulators.
• Compare the three licensing routes available within the European Union and when each one applies.
• Describe how licenses are reviewed and renewed across a medicine's life cycle.
• Recognize the pharmaceutical company's responsibility in maintaining license validity through clinical evidence.

Who Should Attend?

• Anyone connected to public health issues, directly or indirectly.
• Professionals working in healthcare and pharmaceuticals.
• Managers and coordinators in medical treatment and pharmaceutical departments.
• Medical field staff.
• Graduates of pharmacy, nutrition and related disciplines.

Module 1: Why Drug Regulation Matters

• The link between drug regulation and quality health management
• Pharmaceutical companies' role in patient safety
• Consequences of weak regulatory oversight

Module 2: Global Regulatory Bodies

• The FDA and its scope of authority
• The European Medicines Evaluation Agency (EMEA)
• The Japanese Pharmaceutical Affairs Office
• How local regulators coordinate with these bodies

Module 3: Licensing Pathways in the European Union

• Direct application to the EMEA (mandatory for biopharmaceuticals, optional for new pharmaceutical products)
• Nomination of a member government with mutual recognition by other states
• National licensing for products marketed in a single country

Module 4: Managing a License Across the Drug Life Cycle

• Review cycles: every six months for the first two years, then annually for up to five years
• The pharmaceutical company's renewal responsibilities
• Using the four phases of clinical trials as supporting evidence

Module 5: Pharmacology, Quality and Market Access

• Objectives of pharmacology and drug study patterns
• Quality control of medicines and treatments
• Marketing and sale of pharmaceutical products
• Duration and bodies responsible for approving treatments

Course Locations:

The course is held in Egypt, Jordan, Malaysia, Turkey, England, France, Italy, Germany, Sweden, Austria, Denmark, Australia and the United States, at times and places that suit your schedule.

Delivery Formats:

• Group training at Academy centers
• Individual training
• Field and practical training
• Theoretical training in dedicated halls

What Participants Receive:

A certificate accredited by the Arab British Fellowship Training Academy upon completing the program.